New AI model can evaluate invasive breast cancer outcomes
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
List view / Grid view
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).
A study has demonstrated the success of new compounds that prevent FOXM1, a transcription factor, from increasing cancer proliferation.
Researchers have made a unique discovery about the role of the MED1 protein in breast cancer formation, showing it to be a promising therapeutic target worthy of future study.